Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer
Cancer-derived inflammation appears to play a crucial role in mediating both intrinsic and acquired resistance to Bev. The FPR emerges as a robust, independent biomarker for predicting response to Bev, monitoring disease progression, and informing personalized therapeutic decision-making in patients with mCRC.
Authors
- Cheng Xue‐Xin
- Peng Tian (ORCID: https://orcid.org/0009-0005-7313-2885)
- Ying Lu (ORCID: https://orcid.org/0000-0002-3032-0318)
- Lin Xiang
- Ya-Nan Li
- Guobin Song
- Feng-Wen Deng
- Hou-Qun Ying
- Yang Wu
Institutions
- Shangrao Normal University (CN)
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Hubei Polytechnic University (CN)
- Daye People's Hospital (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1177/17588359251411086
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00